Home » PHARMACYCLICS TO SUBMIT NEW DRUG APPLICATION FOR XCYTRIN
PHARMACYCLICS TO SUBMIT NEW DRUG APPLICATION FOR XCYTRIN
Pharmacyclics will submit a new drug application (NDA) to the FDA to market Xcytrin (motexafin gadolinium) Injection for the treatment of non-small cell lung cancer (NSCLC) patients with brain metastases (i.e., lung cancer that has spread to the brain from another part of the body).
New data from a late-stage trial, called the SMART trial, will be included in the application. The data showed, according to a presentation that will be made at an upcoming conference, that Xcytrin combined with prompt whole brain radiation therapy prolongs time to neurologic progression of the lung cancer.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May